Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?
In dialysis patients the humoral response to anti-SARS-CoV-2 vaccines is attenuated and rapidly declines over time. However, data on the persistence of the immune response in peritoneal dialysis (PD) patients are scarce, particularly after a third (booster) dose with mRNA-1273 vaccine. In this prosp...
Main Authors: | Georg Beilhack, Rossella Monteforte, Florian Frommlet, Roman Reindl-Schwaighofer, Robert Strassl, Andreas Vychytil |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.905798/full |
Similar Items
-
Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave
by: Georg Beilhack, et al.
Published: (2023-06-01) -
Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization
by: Ficociello LH, et al.
Published: (2022-11-01) -
Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
by: Sammy Patyna, et al.
Published: (2022-04-01) -
Peritoneal Dialysis-Associated Peritonitis
by: Funda TİMURKAYNAK
Published: (2006-09-01) -
Construction and validation of a predictive model for the risk of peritoneal dialysis-associated peritonitis after peritoneal dialysis catheterization
by: Rong Dai, et al.
Published: (2023-09-01)